Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2017

01-06-2017 | Original Article

Medical Therapies for Stricturing Crohn’s Disease: Efficacy and Cross-Sectional Imaging Predictors of Therapeutic Failure

Authors: Cécile Campos, Antoine Perrey, Céline Lambert, Bruno Pereira, Marion Goutte, Anne Dubois, Felix Goutorbe, Michel Dapoigny, Gilles Bommelaer, Constance Hordonneau, Anthony Buisson

Published in: Digestive Diseases and Sciences | Issue 6/2017

Login to get access

Abstract

Background

Medical therapy efficacy remains controversial in stricturing Crohn’s disease. Cross-sectional imaging, especially magnetic resonance imaging, has been suggested as very helpful to guide therapeutic decision making.

Aim

To assess efficacy and predictors of therapeutic failure in patients receiving medical treatments for stricturing Crohn’s disease.

Methods

In this retrospective study, therapeutic failure was defined as symptomatic stricture leading to surgical or endoscopic therapeutics, hospitalization, treatment discontinuation or additional therapy and short-term clinical response as clinical improvement assessed by two physicians. The 55 cross-sectional imaging examinations (33 magnetic resonance imaging and 22 CT scan) before starting medical therapy were analyzed independently by two radiologists. Results were expressed as hazard ratio (HR) or odds ratio (OR) with 95% confidence intervals (95% CI).

Results

Among 84 patients, therapeutic failure rate within 60 months was 66.6%. In multivariate analysis, Crohn’s disease diagnosis after 40 years old (HR 3.9, 95% CI [1.37–11.2], p = 0.011), small stricture luminal diameter (HR 1.34, 95% CI [1.01–1.80], p = 0.046), increased stricture wall thickness (HR 1.23, 95% CI [1.04–1.46], p = 0.013) and fistula with abscess (HR 5.63, 95% CI [1.64–19.35], p = 0.006) were associated with therapeutic failure, while anti-TNF combotherapy (HR 0.17, 95% CI [0.40–0.71], p = 0.015) prevented it. Considering 108 therapeutic sequences, the short-term clinical response rate was 65.7%. In multivariate analysis, male gender (OR 0.15, 95% CI [0.03–0.64], p = 0.011), fistula with abscess (OR 0.09, 95% CI [0.01–0.77], p = 0.028) and comb sign (OR 0.23, 95% CI [0.005–0.97], p = 0.047) were associated with short-term clinical failure.

Conclusion

Anti-TNF combotherapy seemed to prevent therapeutic failure, and cross-sectional imaging should be systematically performed to help medical management in stricturing Crohn’s disease.
Appendix
Available only for authorised users
Literature
2.
go back to reference Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis. 2010;16:15–22. doi:10.1002/ibd.21010.CrossRefPubMed Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis. 2010;16:15–22. doi:10.​1002/​ibd.​21010.CrossRefPubMed
3.
go back to reference Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut. 2012;61:241–247. doi:10.1136/gutjnl-2011-300049.CrossRefPubMed Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut. 2012;61:241–247. doi:10.​1136/​gutjnl-2011-300049.CrossRefPubMed
6.
9.
go back to reference Zappa M, Stefanescu C, Cazals-Hatem D, et al. Which magnetic resonance imaging findings accurately evaluate inflammation in small bowel Crohn’s disease? A retrospective comparison with surgical pathologic analysis. Inflamm Bowel Dis. 2011;17:984–993. doi:10.1002/ibd.21414.CrossRefPubMed Zappa M, Stefanescu C, Cazals-Hatem D, et al. Which magnetic resonance imaging findings accurately evaluate inflammation in small bowel Crohn’s disease? A retrospective comparison with surgical pathologic analysis. Inflamm Bowel Dis. 2011;17:984–993. doi:10.​1002/​ibd.​21414.CrossRefPubMed
10.
go back to reference Rimola J, Planell N, Rodríguez S, et al. Characterization of inflammation and fibrosis in Crohn’s disease lesions by magnetic resonance imaging. Am J Gastroenterol. 2015;. doi:10.1038/ajg.2014.424. Rimola J, Planell N, Rodríguez S, et al. Characterization of inflammation and fibrosis in Crohn’s disease lesions by magnetic resonance imaging. Am J Gastroenterol. 2015;. doi:10.​1038/​ajg.​2014.​424.
11.
go back to reference Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.CrossRefPubMed Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.CrossRefPubMed
14.
go back to reference Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56:1232–1239.CrossRefPubMedPubMedCentral Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56:1232–1239.CrossRefPubMedPubMedCentral
15.
go back to reference Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterol. 2007;132:52–65.CrossRef Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterol. 2007;132:52–65.CrossRef
16.
go back to reference Louis E, Boverie J, Dewit O, et al. Treatment of small bowel subocclusive Crohn’s disease with infliximab: an open pilot study. Acta Gastro-Enterol Belg. 2007;70:15–19. Louis E, Boverie J, Dewit O, et al. Treatment of small bowel subocclusive Crohn’s disease with infliximab: an open pilot study. Acta Gastro-Enterol Belg. 2007;70:15–19.
18.
19.
go back to reference Condino G, Calabrese E, Zorzi F, et al. Anti-TNF-alpha treatments and obstructive symptoms in Crohn’s disease: a prospective study. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2013;45:258–262. doi:10.1016/j.dld.2012.10.009. Condino G, Calabrese E, Zorzi F, et al. Anti-TNF-alpha treatments and obstructive symptoms in Crohn’s disease: a prospective study. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2013;45:258–262. doi:10.​1016/​j.​dld.​2012.​10.​009.
20.
go back to reference Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2006;4:621–630. doi:10.1016/j.cgh.2006.03.002. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2006;4:621–630. doi:10.​1016/​j.​cgh.​2006.​03.​002.
22.
go back to reference Pallotta N, Barberani F, Hassan N-A, Guagnozzi D, Vincoli G, Corazziari E. Effect of infliximab on small bowel stenoses in patients with Crohn’s disease. World J Gastroenterol. 2008;14:1885–1890.CrossRefPubMedPubMedCentral Pallotta N, Barberani F, Hassan N-A, Guagnozzi D, Vincoli G, Corazziari E. Effect of infliximab on small bowel stenoses in patients with Crohn’s disease. World J Gastroenterol. 2008;14:1885–1890.CrossRefPubMedPubMedCentral
23.
go back to reference Bouhnik Y, Carbonnel F, Laharie D, et al. 287 Efficacy of adalimumab in patients with Crohn’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort study (CREOLE). Gastroenterology. 2015;148:S-62. doi:10.1016/S0016-5085(15)30216-X.CrossRef Bouhnik Y, Carbonnel F, Laharie D, et al. 287 Efficacy of adalimumab in patients with Crohn’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort study (CREOLE). Gastroenterology. 2015;148:S-62. doi:10.​1016/​S0016-5085(15)30216-X.CrossRef
24.
go back to reference Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2. (discussion 6-19).CrossRefPubMed Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2. (discussion 6-19).CrossRefPubMed
25.
go back to reference Buisson A, Filippi J, Amiot A, et al. Su1229 Definitions of the endoscopic lesions in Crohn’s disease: reproductibility study and GETAID expert consensus. Gastroenterology. 2015;148:S-445. doi:10.1016/S0016-5085(15)31500-6. Buisson A, Filippi J, Amiot A, et al. Su1229 Definitions of the endoscopic lesions in Crohn’s disease: reproductibility study and GETAID expert consensus. Gastroenterology. 2015;148:S-445. doi:10.​1016/​S0016-5085(15)31500-6.
26.
go back to reference Buisson A, Joubert A, Montoriol P-F, et al. Diffusion-weighted magnetic resonance imaging for detecting and assessing ileal inflammation in Crohn’s disease. Aliment Pharmacol Ther. 2013;37:537–545. doi:10.1111/apt.12201.CrossRefPubMed Buisson A, Joubert A, Montoriol P-F, et al. Diffusion-weighted magnetic resonance imaging for detecting and assessing ileal inflammation in Crohn’s disease. Aliment Pharmacol Ther. 2013;37:537–545. doi:10.​1111/​apt.​12201.CrossRefPubMed
27.
go back to reference Hordonneau C, Buisson A, Scanzi J, et al. Diffusion-weighted magnetic resonance imaging in ileocolonic Crohn’s disease: validation of quantitative index of activity. Am J Gastroenterol. 2014;109:89–98. doi:10.1038/ajg.2013.385.CrossRefPubMed Hordonneau C, Buisson A, Scanzi J, et al. Diffusion-weighted magnetic resonance imaging in ileocolonic Crohn’s disease: validation of quantitative index of activity. Am J Gastroenterol. 2014;109:89–98. doi:10.​1038/​ajg.​2013.​385.CrossRefPubMed
28.
go back to reference Buisson A, Hordonneau C, Goutte M, et al. Diffusion-weighted magnetic resonance enterocolonography in predicting remission after anti-TNF induction therapy in Crohn’s disease. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2015;. doi:10.1016/j.dld.2015.10.019. Buisson A, Hordonneau C, Goutte M, et al. Diffusion-weighted magnetic resonance enterocolonography in predicting remission after anti-TNF induction therapy in Crohn’s disease. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2015;. doi:10.​1016/​j.​dld.​2015.​10.​019.
29.
go back to reference Buisson A, Hordonneau C, Goutte M, Boyer L, Pereira B, Bommelaer G. Diffusion-weighted magnetic resonance imaging is effective to detect ileocolonic ulcerations in Crohn’s disease. Aliment Pharmacol Ther. 2015;. doi:10.1111/apt.13287.PubMed Buisson A, Hordonneau C, Goutte M, Boyer L, Pereira B, Bommelaer G. Diffusion-weighted magnetic resonance imaging is effective to detect ileocolonic ulcerations in Crohn’s disease. Aliment Pharmacol Ther. 2015;. doi:10.​1111/​apt.​13287.PubMed
30.
go back to reference Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–381. doi:10.1016/j.jbi.2008.08.010.CrossRefPubMed Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–381. doi:10.​1016/​j.​jbi.​2008.​08.​010.CrossRefPubMed
31.
go back to reference Bossuyt P, Debeuckelaere C, Billiet T, et al. Su1814 The need for surgery in stricturing ileal CD Is linked to clinical and imaging factors but independent of NOD2 genotype. Gastroenterology. 2016;150:S560. doi:10.1016/S0016-5085(16)31913-8.CrossRef Bossuyt P, Debeuckelaere C, Billiet T, et al. Su1814 The need for surgery in stricturing ileal CD Is linked to clinical and imaging factors but independent of NOD2 genotype. Gastroenterology. 2016;150:S560. doi:10.​1016/​S0016-5085(16)31913-8.CrossRef
Metadata
Title
Medical Therapies for Stricturing Crohn’s Disease: Efficacy and Cross-Sectional Imaging Predictors of Therapeutic Failure
Authors
Cécile Campos
Antoine Perrey
Céline Lambert
Bruno Pereira
Marion Goutte
Anne Dubois
Felix Goutorbe
Michel Dapoigny
Gilles Bommelaer
Constance Hordonneau
Anthony Buisson
Publication date
01-06-2017
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2017
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4572-4

Other articles of this Issue 6/2017

Digestive Diseases and Sciences 6/2017 Go to the issue